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Abstract
We present a probabilistic programmed deep kernel learn-
ing approach to personalized, predictive modeling of neu-
rodegenerative diseases. Our analysis considers a spectrum
of neural and symbolic machine learning approaches, which
we assess for predictive performance and important med-
ical AI properties such as interpretability, uncertainty rea-
soning, data-efficiency, and leveraging domain knowledge.
Our Bayesian approach combines the flexibility of Gaus-
sian processes with the structural power of neural networks
to model biomarker progressions, without needing clinical
labels for training. We run evaluations on the problem of
Alzheimer’s disease prediction, yielding results surpassing
deep learning and with the practical advantages of Bayesian
non-parametrics and probabilistic programming.
Introduction
Accurate prediction of disease trajectories is critical for
informing decisions, particularly in the earliest phases of
disease where action can be impactful. Machine learning
methods show promise in diagnostics, but mainstream neu-
ral network methods struggle to model longitudinal disease
biomarkers to predict disease trajectories. Even more, they
are ineffective with sparse and limited data that is common
in clinical cohorts, and the deep learning methods are diffi-
cult to trust due to lack of interpretable mechanisms. Proba-
bilistic generative models, on the other hand, are well-suited
to the task of disease modeling. This class of methods allows
quantification and reasoning with uncertainties, is robust to
sparse and noisy data, yields interpretable models and pre-
dictions, and can utilize prior information and structure en-
coded by domain experts. Probabilistic programming, a rel-
atively new area at the intersection of artificial intelligence
and programming languages, provides the ideal representa-
tion of these models in software. A probabilistic model in
the form of probabilistic program code describes the data-
generating process from unknown latent variables to ob-
served data, and in general the languages enable automatic
inference over arbitrary programs. The types of models that
may be written as probabilistic programs include not only
basic Bayesian networks and graphical models, but also ones
more expressive and flexible, such as non-parametric models
and graphical models with dynamic structure.
Preprint. Work in progress.
There have been many successful uses of probabilistic
programming and neural networks in medical AI. Yet pre-
dictive modeling neurodegenerative diseases presents even
more challenges, mainly due to the complex nature and het-
erogeneity of these conditions. For instance, Alzheimer’s
disease is characterized by dozens of biomarkers ranging
from spinal fluid proteins and genetic precursors to psy-
chophysical assessments and brain MRI, the nature of which
vary widely across the population of patients. Even more,
there are potentially dozens of subtypes of the disease, and
the underlying mechanisms remain relatively unknown. This
is compounded by the data regime, where measurements are
sparse, cohorts are relatively small, and clinical labels are
subjective. To approach the problem of predictive modeling
neurodegeneration, we would ideally leverage the represen-
tational learning capacity of neural networks, while making
use of symbolic methods that operate with little data and en-
able experts to encode rich domain knowledge.
We propose such a neuro-symbolic approach that inte-
grates the flexibility of Bayesian non-parametrics, the fea-
ture learning of neural networks, and the expressive capabil-
ities of probabilistic programming. Our main contributions
are the following:
• We build on the work of deep kernel learning (Wilson
et al. 2016a) to develop probabilistic programmed deep
kernel learning (PP-DKL), which enables us to improve
the biomarker modeling with “kernel warping” and mono-
tonic Gaussian processes.
• We discuss and evaluate a spectrum of machine learning
approaches towards neurodegenerative disease modeling:
from data-driven neural networks to domain-engineered
graphical models and statistical methods.
• We show our PP-DKL method achieves state-of-the-art
results on predicting neurodegeneration in Alzheimer’s
disease, along with practical advantages such as model
interpretability and uncertainty reasoning.
Background
Probabilistic Programming
Probabilistic programming languages (PPL) represent prob-
abilistic generative models as programs written in a special-
ized language that provides syntax for the definition and
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conditioning of random variables (Goodman et al. 2008;
Mansinghka, Selsam, and Perov 2014; Wood, van de Meent,
and Mansinghka 2014; Goodman and Stuhlmu¨ller). Specifi-
cally, a PPL implements two required constructs: the ability
to draw values at random from distributions, and the abil-
ity to condition values of variables (which allow data from
real world observations to be incorporated into a probabilis-
tic program) (Gordon et al. 2014). This is typically accom-
plished with sampling and conditioning primitives sample
and observe, respectively, embedded in a host language
such as Python (Bingham et al. 2019), C/C++ (Lavin and
Mansinghka 2018; Paige and Wood 2014), and Julia (Ge,
Xu, and Ghahramani 2018). Importantly, the set of random
variables is dynamically typed such that programs may dif-
fer from execution to execution.
Core to PPL design is the decoupling of modeling and
inference; model code is generally concise and modu-
lar, and inference algorithms are capable of operating on
arbitrary programs. These general-purpose “inference en-
gines” are typically implemented as forward-simulation
sampling methods (namely Sequential Monte Carlo and par-
ticle MCMC (Andrieu, Doucet, and Holenstein 2010)) or
variational inference. Because probabilistic programs are
dynamic and stochastic by nature, these engines must be
flexible to support dynamic computation graphs. More ef-
ficient PPS such as the BUGS language (Lunn et al. 2000)
and infer.NET (Winn and Minka 2009) construct the com-
putation graph ahead of inference and then run message
passing on the fixed graph. This however constrains the
set of possible programs. An encouraging feature of prob-
abilistic programs is stochastic branching, which can only
be supported with alternative inference algorithms that are
more general-purpose. Thus, most inference engines for uni-
versal probabilistic programming languages use forward-
simulation based sampling methods, as we do here.
A model program specifies a joint distribution p(y,x)
over data y and variables x. Inference aims to character-
ize the distribution of program execution traces: a map from
random choices to their specific values. In other words, a
generative model is compiled to a form that can be inter-
preted by an inference engine, which then outputs some
characterization of the posterior such as a series of samples.
Formally the probability of an execution trace can be defined
as
p(y,x) =
N∏
n=1
p(yn|ζgn ,xn)p(xn|xn−1)
where yn is the n-th observe’d data point, p(yn|ζgn) is
its normalized likelihood, ζgn(xn) is the program argument
with random procedures gn(xn), xn is the ordered set of all
random choices with p(xn|xn−1) its normalized prior prob-
ability, and x and y are the sets of all latent and observing
random procedures, respectively (Wood, van de Meent, and
Mansinghka 2014).
For more detailed derivation and further information on
probabilistic programming we refer the reader to the recent
tutorial of van de Meent et al. (2018).
Neurodegenerative Disease Modeling
Neurodegenerative disorders such as Alzheimer’s disease
are characterised by the progressive pathological alteration
of the brain’s biochemical processes and morphology, lead-
ing to irreversible impairment of cognitive functions. These
diseases are uniquely challenging to model computationally
due to heterogeneous biological pathways (Beckett et al.
2015; Hardy and Selkoe 2002), complex temporal patterns
(Jedynak et al. 2015; Donohue et al. 2014), and diverse in-
teractions (Froelich et al. 2017; Pascoal et al. 2017). The
driving aim for longitudinal modeling Alzheimer’s disease
is to provide predictions that enable early detection of at-
risk subjects and possibly reveal latent disease mechanisms.
Statistical techniques for longitudinal disease modeling
are ubiquitous, most commonly generalized linear or non-
linear mixed-effects models (Laird and Ware 1982; Lind-
strom and Bates 1990), and various survival models such as
the Cox proportional hazards (Cox 1992). These models of-
ten assume linearity and proportionality in the underlying
stochastic disease process, which makes them ill-suited to
model the complexities of neurodegenerative processes.
More promising statistical approaches apply joint mixed-
effects models to uncover longitudinal trends across patho-
logical abnormalities, notably the approach of Li et al.
(2019) that constructs a generative model for individual
biomarker progressions. More general is the continuous-
time HMM for disease progression from Liu et al. (2015),
specifically to account for irregular sampling of longitudi-
nal data and hidden state-transition times. Their approach
yields interpretable trajectories as state transition trends (as
does ours), which is a rather useful research and prognostic
tool, but the method does not provide predictive modeling.
Bayesian non-parametric methods are promising, notably
Gaussian Processes as powerful probabilistic predictors of
dementia risk (Peterson et al. 2017; Ziegler et al. 2014;
Lorenzi et al. 2017; Hyun et al. 2016; Rudovic et al. 2019).
For the most part these approaches rely heavily on cogni-
tive assessment scores and clinical status, and mainly model
population-level statistics. The result is inability to model
early phases of Alzheimer’s, nor individual-specific patholo-
gies.
Neural network approaches, as general-purpose function
approximators, may be well-suited to the complexities inher-
ent in modeling Alzheimers disease. Using deep convolu-
tional neural networks, state-of-the-art vision-based results
were shown by Ding et al. (2019), but with subpar perfor-
mance in early neurodegeneration, let alone the presymp-
tomatic phases. We hypothesize restricting biomarkers to
the visual modality sets a bound on how early a model can
predict neurodegeneration. Similarly, clinical measures such
as cognitive assessments are far too late; research suggests
that brain changes associated with the disease begin upwards
of 20 years before cognitive symptoms may appear (Ville-
magne et al. 2013). Match-Net (Jarrett, Yoon, and van der
Schaar 2020) is a promising deep learning approach that ag-
gregates the biomarker modalities into one deep network,
and models longitudinal dependencies with temporal convo-
lutions. Even more, to help address data sparsity issues that
are common in neurodegenerative patient populations, the
model learns correlations between missing data and disease
progression. The authors show state-of-the-art results on the
task of Alzheimer’s risk scoring, but in a fully supervised
way towards an ill-defined task. That is, most existing ap-
proaches focus on modeling patients based on their clinical
status, i.e. the clinical diagnosis categorizing them into one
of the three main stages of Alzheimer’s: cognitively normal
(CN), mild cognitive impairment (MCI), and Alzheimer’s
dementia (AD). These labels are largely subjective and qual-
itative; misdiagnosis is pervasive in practice (Jobke et al.
2018). We stress that any machine learning model trained
on Alzheimer’s clinical labels is thus ill-defined.
Thus, for Alzheimer’s predictive modeling, it is impera-
tive for approaches to learn unsupervised (i.e. not training
on unreliable clinical labels). Several additional properties
are highly desirable in medical AI in general: interpretabil-
ity, uncertainty reasoning, longitudinal modeling, account-
ing for inconsistent sampling and missing observations in
clinical data. These qualities tend to be drawbacks of neural
network approaches1, while being advantages of more sym-
bolic methods.
Proposed Method
We first define the problem of predictive modeling neu-
rodegeneration, and then our neuro-symbolic approach with
neural networks, Gaussian processes, and probabilistic pro-
gramming.
Problem Formulation
Given previous biomarker measurements from individual
patients, we aim to predict their cognitive capabilities in
the future. This task avoids the unreliability of Alzheimer’s
clinical labels, while also being more useful in practice,
as this prediction capability is valuable towards personal-
ized prognosis and clinical trials. We aim to predict the
key cognitive decline metrics for Alzheimer’s progression
(MMSE, ADAS-Cog13, and CDRSB) corresponding to
length-τ horizons into the future.
Let there be N subjects in a study, from which there are
K observation (response) variables measured at different
follow-up times. The K observation variables can be a mix
of binary, ordinal, or continuous measurements/outcomes.
We denote the measured biomarker k for individual i at time
j as xijk, where i = 1...N , k = 1...K, j = 1...qik. Note
q is used to count the number of measurements of k for
individual i, as we must allow for the sampling to be var-
ied and sparse. The outcome scores for single patient vis-
its are stored as yi = {MMSE ∈ (0, 30),ADAS-Cog13 ∈
(0, 85),CDRSB ∈ (0, 18)}, and Y = {yi}Ni=1. Furthermore,
each patient is represented by data pairs: {xi, yi}, where
xi = {x1, ..., xt} contains the input features (i.e. biomarker
values) up to visit t of T .
1That’s not to say there isn’t notable work in making deep learn-
ing disease modeling more interpretable, namely (Alaa and Schaar
2018).
Gaussian Processes
A GP is a stochastic process which is fully specified by
its mean function and covariance function such that any fi-
nite set of random variables have a joint Gaussian distri-
bution (Rasmussen and Williams 2005). GPs provide a ro-
bust method for modeling non-linear functions in a Bayesian
nonparametric framework; ordinarily one considers a GP
prior over the function and combines it with a suitable like-
lihood to derive a posterior estimate for the function given
data. GPs are flexible in that, unlike parametric counter-
parts, they adapt to the complexity of the data. Even more,
GPs provide a principled way to reason about uncertainties
(Ghahramani 2015).
A GP defines a distribution over functions f : Rd → R
from inputs to target values:
f(x) ∼ GP (µ(x), kφ (xi,xj))
with mean function µ(x) and covariance kernel function
kφ (xi,xj) parameterized by φ. Any collection of function
values is jointly Gaussian,
f(X) = [f (x1) , . . . , f (xn)]
T ∼ N (µ,KX,X)
with mean vector and covariance matrix defined by the GP,
s.t.µi = µ(xi) and (KX,X)ij = kφ (xi,xj). In practice, we
often assume that observations include i.i.d. Gaussian noise:
y(x) = f(x) + (x), where  ∼ N(0, φ2n), and the covari-
ance function becomes
Cov (y (xi) , y (xj)) = k (xi,xj) + φ2nδij
where δij = I[i = j]. One can then compute a Gaussian
posterior distribution in closed form by conditioning on the
observed data (XL, yL) and make predictions at unlabeled
points XU .
Sparse GP methods have significantly improved the scal-
ability of GP inference, specifically the method of induc-
ing points (Titsias 2009; Hensman, Matthews, and Ghahra-
mani 2015). This approach allows us to make a variational
approximation to the posterior process that is Gaussian and
only uses M << D inducing features (where D is the full
number of data points). This decreases the time and space
complexity fromO(d3) andO(d2), respectively, toO(dm2)
and O(dm).
Monotonic GPs To prior the Gaussian process biomarker
progressions to better model increasing severity of neurode-
generation, we implement montonicity constraints. Specifi-
cally we use the approach of Riihima¨ki and Vehtari (2010),
to include derivatives information at a number of GP input
locations and force the derivative process to be positive at
these locations. In future work we would like to improve on
this with monotonic GP flows (Ustyuzhaninov et al. 2020).
Deep Kernel Learning
Deep kernel learning (DKL) combine the structural proper-
ties of deep architectures with the non-parametric flexibility
Figure 1: Two-dimensional embeddings learned by a DKL model (left) and our probabilistic programmed version (right);
the colorbar shows the magnitude of the normalized outputs. In the left panel, DKL learns a poor embedding, where colors
representing different output magnitudes are intermingled. In the right panel, PP-DKL is able to learn a better representation
of the dataset; kernel warping creates a cohesive deep kernel, yielding inducing points that lie in the original data space rather
than the neural network feature space.
of kernel methods (Wilson et al. 2016a). Specifically com-
bining deep neural networks with Gaussian process yields
several useful characteristics:
• The information capacity of the model grows with the
amount of available data (as a non-parametric method),
but its complexity is automatically calibrated through the
marginal likelihood of the GP.
• The non-parametric GP layer provides flexibility and au-
tomatic calibration, and typically high performance (in
the face of noise). This helps reduce the need for extensive
hand tuning from the user.
• Inference and learning procedures for O(n) training and
O(1) testing time.
Given input data x ∈ X , a neural network parameterized
by w is used to extract features hw(x) ∈ R. The outputs are
modeled as
f(x) ∼ GP (µ (hw(x)) , kφ (hw (xi) , hw (xj)))
for some mean function µ(·) and covariance kernel function
kφ (·, ·) with parameters φ. Parameters θ = (w, φ) of the
deep kernel are learned jointly by minimizing the negative
log-likelihood of the labeled data: − log p (yL | XL, θ). For
Gaussian distributions, the marginal likelihood is a closed-
form, differentiable expression, allowing DKL models to be
trained via backpropagation.
Probabilistic Programmed DKL A standard approach to
DKL is to apply GPs to the feature-level outputs of a NN,
one GP per feature. This representation yields GP inducing
points in feature-space H . Ma, Ganapathiraman, and Zhang
(2019) show kernel “warping” to induce feature representa-
tions that respect invariances that reach beyond transforma-
tion. In this context, we would want to “warp” the GP with
the neural network feature extractor to produce a deep ker-
nel kwarped that yields inducing points in the space of the
original data X:
kwarped(x, h) = q(k(f(x), f(h)))
This can be readily implemented in probabilistic program-
ming by defining the combined deep kernel within a prob-
abilistic program, which can then be simply used by the
MCMC black-box inference engine as usual. Otherwise a
complex, custom inference methods are called for. We refer
to this approach as probabilistic-programmed deep kernel
learning (PP-DKL).
To gain some intuition about how the warping helps the
model learn a better representation, we visualize the neu-
ral network embeddings learned by the DKL and PP-DKL
models on the Alzheimer’s dataset (ADNI, described in the
Experiments section) in Fig. 1. The left plot shows DKL
learns a rather poor embedding, where different colors rep-
resenting different output magnitudes are intermingled. Yet
the warped deep kernel resulting from PP-DKL yields em-
beddings that better represent the dataset, as shown in the
right plot.
Neurodegeneration Programs
A probabilistic model in the form of probabilistic program
code describes the data-generating process from unknown
latent variables values to observed data. We posit the un-
derlying disease state is represented by a latent stochastic
process that manifests as a series of observable biomarkers.
We encode additional domain knowledge by using mono-
tonic GPs to model how each biomarker deteriorates over
time, in agreement with main Alzheimer’s progression hy-
potheses (Jedynak et al. 2015). The model is trained on pop-
ulation level data to capture general statistics for biomarker
progressions. Individual instances of a “neurodegeneration
program” are fed a patient’s observed data in the form of
biomarker values, and predicts their individual biomarker
progressions. A neurodegeneration program can be used as
a simulator of a patient’s latent disease process; the pro-
gram defines a statistical model with random samplings,
from which we can generate probabilistic trajectories for in-
dividual biomarkers.
We note that GP mean and variance is propagated
throughout program execution, so quantifying the specific
uncertainties with PP-DKL is trivial; we can sample model
programs for aleatoric (system stochasticity such as obser-
vation and process noise) and epistemic (subjective uncer-
tainty due to limited data) uncertainty measures.
We implement PP-DKL in the “Pyro” probabilistic pro-
gramming language (which is embedded in Python and
leverages PyTorch) (Bingham et al. 2019).
Experiments
We experiment with data from the Alzheimers Disease
Neuroimaging Initiative (ADNI), a multicohort longitudinal
study in which volunteers diagnosed as cognitively healthy
or with various degrees of cognitive impairment have been
evaluated since 2005 (adni.loni.usc.edu). ADNI subjects
are evaluated via neuroimaging (PET), cerebrospinal fluid
(CSF), and other biomarkers, as well as clinical and neu-
ropsychological assessments. As discussed earlier, the di-
agnostic labels in ADNI are ill-defined and thus an unsuit-
able task (here and in clinical practice). We thus emphasize
the task of cognitive scoring predictions corresponding to
length-τ horizons into the future, rather than diagnostic clas-
sification. We downloaded the standard dataset processed for
the TADPOLE Challenge (Marinescu et al. 2018), represent-
ing 1,737 unique patients.
To evaluate performance we follow the specifications of
(Peterson et al. 2017): we ran a 10-fold patient-independent
cross-validation, and report the mean absolute error (MAE)
and intra-class correlation (ICC (3,1)) metrics. The latter
ranges from 01, and is used to measure the (absolute) agree-
ment between the model predictions and the ground-truth
for target scores. Table 1 reports the mean ±SD of the 10-
folds. All the input features were z-normalized, and we then
applied principal component analysis to reduce the effects
of noise in the data, preserving 95% of variance. Note the
experiments in (Peterson et al. 2017) select a subset of pa-
tients above a certain threshold of data points. However we
do not do this, as it is important to evaluate the robustness of
methods to sparseness in clinical data.
Baselines: neural nets to symbolic models. We evalu-
ate a spectrum of neurodegenerative disease modeling ap-
proaches, from neural network models with massive param-
eter spaces that learn nearly any relevant function approxi-
mation, to methods that are strongly-specified with domain
and mechanistic details. At the tabula-rasa end of the spec-
trum we have deep learning approaches which aim to au-
tomatically discover good feature representations through
end-to-end optimization of neural networks. We specifi-
cally evaluate Match-Net (Jarrett, Yoon, and van der Schaar
2020), the leading deep learning approach in this domain,
and a baseline recurrent neural networks (RNN). At the in-
tersection of neural networks and symbolic AI, we have
deep kernel learning. Specifically we compare several vari-
ations: DKL is the standard approach from (Wilson et al.
2016b), PP-DKL is our probabilistic programmed deep ker-
nel approach, and PP-DKL’ is without the monotonicity con-
straints. All DKL methods use the same feature-extractor
network architecture (similar to (Wilson et al. 2016a)): [d−
100− 50− 50− 2]. Moving along the spectrum away from
neural networks, we run the auto-regressive personalized
GP (pGP) of (Peterson et al. 2017), and finally a conven-
tional statistical method, joint modeling (JM). Note we do
not run the purely mechanistic approach of ordinary differ-
ential equations as these have not been shown to perform
well in predictive modeling neurodegenerative diseases. All
models are implemented in PyTorch, and code will be open-
source with publication.
Further details on the dataset and models are provided in
the Appendix.
Results
The results are shown in Table 1. Notice we sort the mod-
els top-down, progressively becoming more “pure” neural
network, with our neuro-symbolic approach PP-DKL listed
in the middle. We find PP-DKL in general outperforms all
other methods, across the cognitive score predictions and
metrics. Relative to the other deep kernel variations, we
observe that both kernel-warping and the GP monotonicity
constraints on biomarker progressions improve performance
as expected; interestingly, the monotonic GPs show tighter
variance in general.
As expected from the results in Jarrett, Yoon, and van der
Schaar (2020), we also see Match-Net outperforming the
RNN baseline on the neurodegeneration prediction tasks. In-
terestingly, the performance difference is exacerbated in the
neurodegeneration task here, which is more challenging than
the fully supervised, risk-scoring task in their prior work.
An important component of Match-Net that behooves lon-
gitudinal disease modeling is parameterizing a window for
which to use historical measurements; comparatively, recur-
rent models may consume the entire history, and at the other
extreme a Cox model only utilizes the most recent measure-
ment. This is a prime example of building specific induc-
tive biases in neural networks as a means of encoding prior
knowledge (albeit minimal) for a specific task. Nonethe-
less, Match-Net (and deep learning approaches in general),
are not well-suited for the task of predicting neurodegen-
eration as they require vast quantities of labeled data, and
suffer from miscalibration and lack of interpretable mecha-
nisms. PP-DKL, on the other hand, is data-efficient due to
implicit modeling structure, and well-calibrated because the
Bayesian formulation provides a posterior over predictions.
Interpretability being an important feature in medical AI,
we point out that model interpretability in general decreases
as we move down the list of methods in Table 1. This is yet
another advantage of our probabilistic programming formu-
lation of DKL: probabilistic programs are interpretable by
definition (Ghahramani 2015).
Table 1: Comparison of models on neurodegeneration prediction task. See text for details.
Models MAE ICC
MMSE (0-30) A-Cog13 (0-85) CDRSB (0-18) MMSE (0-30) A-Cog13 (0-85) CDRSB (0-18)
JM 5.76± 0.91 7.20± 1.01 1.73± 0.08 0.41± 0.20 0.62± 0.06 0.74±0.08
pGP 2.18± 0.42 4.99± 0.92 0.91± 0.11 0.71± 0.10 0.79± 0.08 0.86± 0.09
PP-DKL 1.56± 0.27 4.21± 0.09 0.62± 0.06 0.83± 0.11 0.86± 0.06 0.92± 0.04
PP-DKL’ 1.66± 0.36 4.34± 0.68 0.64± 0.07 0.82± 0.13 0.83± 0.07 0.91± 0.05
DKL 1.82± 0.26 4.52± 0.58 0.77± 0.05 0.76± 0.06 0.79± 0.08 0.88± 0.08
Match-Net 1.67± 0.20 4.71± 0.51 0.60± 0.05 0.76± 0.07 0.80± 0.10 0.89± 0.10
RNN 4.11± 0.92 6.96± 0.98 0.91± 0.11 0.50± 0.19 0.69± 0.10 0.75± 1.0
We also note what these results imply for early interven-
tions in Alzheimer’s disease: The known progression of neu-
rodegenerative processes (Jedynak et al. 2015) suggests the
longitudinal biomarkers we used as model inputs precede
cognitive decline upwards of 100 months. Thus, for a model
to perform well on our task, it must be able to predict cogni-
tive decline well into the future. This result is imperative in
Alzheimer’s disease where interventions must target the ear-
liest, presymptomatic phases in order to make a difference.
Conclusion
We have presented a novel probabilistic programmed deep
kernel learning (PP-DKL) approach that performs state-
of-the-art in predicting cognitive decline in Alzheimer’s
disease. Our neuro-symbolic approach has advantageous
medical-AI characteristics such as data-efficiency, model
and prediction interpretability, and principled uncertainty
reasoning. At a higher level, we have compared two per-
spectives on AI-based longitudinal disease modeling: data-
driven with neural networks, and domain-engineered with
probabilistic programs.
We suggest PP-DKL will perform well in other disease
areas, namely Parkinson’s, CTE, and other neurodegenera-
tive conditions, which is an important direction of our future
work.2 Note the preference of PP-DKL over deep learning
is most likely true for heterogeneous diseases with smaller
datasets.
Another important direction to pursue with PP-DKL is to-
wards diagnostic and prognostic algorithms. One can utilize
the “neurodegeneration programs” as personalized disease
simulators, potentially towards counterfactual reasoning and
causal inference (Richens, Lee, and Johri 2020). Even more,
the programs provide a continuous representation of each in-
dividual’s disease state, i.e. representing neurodegeneration
as a sample-continuous process. Further studies can thus de-
rive an objective, data-driven definition of Alzheimers dis-
ease and subtypes, allowing us to stage and diagnose indi-
viduals in a precise, pathological way.
Broader impact. Artificial intelligence and machine
learning methods offer a lot of promise in medicine and
healthcare. Our PP-DKL method can be a powerful tool in
2We have recently been granted access to clinical trials data and
aim to include results in the final publication.
neurodegenerative disease diagnosis and prognostic mod-
eling; there are over 50 million people globally with
Alzheimer’s disease, and it is the 6th leading cause of death
in the United States. Any diagnosis method, be it human or
machine, in clinical practice runs the risk of errors measured
in human lives. It is imperative that methods such as ours
continue with thorough verification and validation steps (im-
portantly, with medical professionals and other domain ex-
perts in the loop).
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Appendix
Modeling & Training
We experimented with the following kernels:
The standard squared exponential (or radial basis function
(RBF)) kernel:
kRBF (xi,xj) = φ
2
f exp
(
−‖xi − xj‖
2
2
2φ2l
)
with parameters φ2f and φ
2
l for signal variance and charac-
teristic length scale, respectively.
The rational quadratic kernel, which is equivalent to
adding together many RBF kernels with different length
scales:
kRQ (x, x
′) = σ2
(
1 +
(x− x′)2
2α`2
)−α
where parameter α determines the relative weighting of
large-scale and small-scale variations.
Polynomial kernels:
kpoly (xi,xj) =
(
φfx
T
i xj + φl
)p
, p ∈ Z+
Periodic kernels and non-smooth kernels (namely
Matern) would not be suitable for our biomarker progres-
sions.
Our reported results reflect the rational quadratic kernel,
although those results were marginally better than RBF.
Note we train these parameters in the log-domain to en-
force positivity constraints on the kernel parameters and pos-
itive definiteness of the covariance. The parametric neural
networks are regularized with L2 weight decay to reduce
overfitting, and models are implemented and trained in Py-
Torch using the ADAM optimizer.
Dataset Details
Data used in this work was obtained from the Alzheimers
Disease Neuroimaging Initiative (ADNI), a multicohort lon-
gitudinal study in which volunteers diagnosed as cognitively
healthy or with various degrees of cognitive impairment
have been evaluated since 2005 (adni.loni.usc.edu). The re-
cent TADPOLE Challenge (Marinescu et al. 2018) provides
a standardized dataset combining data from the multiple
phases of ADNI and across the study sites. The multi-modal
dataset from the ADNI database we used is comprised of
biomarkers across seven different modalities:
• Three cerebrospinal fluid (CSF) measurements: amyloid-
beta, tau, and phosphorylated tau levels.
• Cognitive assessments: CDR Sum of Boxes (CDRSB),
ADAS-Cog11, ADAS-Cog13, MMSE, RAVLT-
immediate subtype, RAVLT-learning subtype, RAVLT-
forgetting subtype, RAVLT-percent forgetting subtype,
and FAQ. We limit our experiments to only use CDRSB,
ADAS-Cog13, and MMSE, which are the most prevelant
in practice.
• Magnetic resonance imaging (MRI) biomarkers can be
used to quantify atrophy and structural brain integrity
by measuring the volume of specific structures, and with
diffusion tensor imaging (DTI). The volumes of interest
include entorhinal, fusiform, hippocampus, intracranial,
mid-temp, ventricles, and whole brain.
• Demographics: age, gender, ethnicity, race, years of edu-
cation, and marital status. All are categorical variables but
for age and education.
• Alipoprotein E4 variant (APOE E4) gene, known as the
largest generic risk factor for Alzheimer’s disease. Geno-
typing in ADNI determines if each patient has the APOE
E4 gene present, and classifies patients into one of two
genetypes (APGEN1 or APGEN2) based on their alleles.
The clinical measurements are taken at approximate 1/2-
year intervals; the average absolute deviation between orig-
inal values and final timestamps amounts to approximately
4 days. Some studies fix the measurements at exactly six
month timestamps, but we do not. Also note that some stud-
ies eliminate patients with sparse data, e.g. Peterson et al.
(2017) cut 1,737 patients to only 100 with rich, nearly com-
plete data. We do not eliminate patients for sparse data, as
overcoming sparsity is an important capability in real-world
use.
